(Q33711422)

28 July 2017

1 reference

title

Immune effector mechanisms in malaria (English)

1 reference

28 July 2017

0 references

1

Good MF

1 reference

28 July 2017

Doolan DL

2

1 reference

28 July 2017

publication date

1 August 1999

1 reference

Current Opinion in Immunology

28 July 2017

published in

1 reference

28 July 2017

volume

11

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

412-419

1 reference

Rationale for the development of an engineered sporozoite malaria vaccine

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Kinetic constraints on the development of a malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

The T cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Sterile protection of monkeys against malaria after administration of interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Characterization ofin VivoPrimary and Secondary CD8+T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Plasmodium yoelii: Antibody and the maintenance of immunity in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Antibody-independent immunity to reinfection malaria in B-cell-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

The role of TH1 and TH2 cells in a rodent malaria infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Protection of rats against malaria by a transplanted immune spleen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Gamma-globulin and acquired immunity to human malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Maternal antibodies block malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Inhibition of Plasmodium falciparum growth in vitro by CD4+ and CD8+ T cells from non-exposed donors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Is there an interaction between human immunodeficiency virus and Plasmodium falciparum?

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Antibodies to sequences in a non-repeat region of Plasmodium falciparum antigen Pf155/RESA inhibit either cytoadherence or parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Pathways and strategies for developing a malaria blood-stage vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP119) induces protective immunity to blood stage malaria infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2980069-7

7 January 2021

10.1016/S0952-7915(99)80069-7

Identifiers

DOI

1 reference

28 July 2017

1 reference